| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Curative Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.013 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.0051 |
| Beta | 0 |
| 1 Month Change | -52.53% |
| 3 Month Change | -61.36% |
| 1 Year Change | -27.14% |
| 3 Year Change | -88.79% |
| 5 Year Change | 1,274,900.00% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUBT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -49.0% | 3.2% | 1.7% |
| 1Y | -27.1% | 6.0% | 26.3% |
Return vs Industry: CUBT underperformed the US Biotechs industry which returned 7% over the past year.
Return vs Market: CUBT underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| CUBT volatility | |
|---|---|
| CUBT Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CUBT's share price has been volatile over the past 3 months.
Volatility Over Time: CUBT's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 4 | I. Garr | curativebiotech.com |
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease.
Curative Biotechnology, Inc. Fundamentals Summary
| CUBT fundamental statistics | |
|---|---|
| Market cap | US$15.81m |
| Earnings (TTM) | -US$3.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs CUBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUBT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.96m |
| Earnings | -US$3.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0044 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -71.9% |
How did CUBT perform over the long term?
See historical performance and comparison